The present invention relates generally to the inhibition of tumor angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis and the suppression of tumor growth in tumors refractory to an anti-vascular endothelial growth factor (VEGF) treatment, using IL-17 antagonists, such as anti-IL-17 antibodies and other antagonists.